Journal of Clinical Pharmacy and Therapeutics最新文献_第3页

Mechanisms of Guanxinning in Myocardial Infarction: An Integrated Approach Using Network Pharmacology, Molecular Docking, and Experimental Validation 冠心宁治疗心肌梗死的机制：基于网络药理学、分子对接和实验验证的综合研究

IF 2 4区医学

Journal of Clinical Pharmacy and Therapeutics Pub Date : 2026-05-30 DOI: 10.1155/jcpt/6488846

Yu Jiang, Xiaoshuang Li, Qinwei Zhu, Chunli Huang, Jiangyue Liu, Ruijian Li

{"title":"Mechanisms of Guanxinning in Myocardial Infarction: An Integrated Approach Using Network Pharmacology, Molecular Docking, and Experimental Validation","authors":"Yu Jiang, Xiaoshuang Li, Qinwei Zhu, Chunli Huang, Jiangyue Liu, Ruijian Li","doi":"10.1155/jcpt/6488846","DOIUrl":"https://doi.org/10.1155/jcpt/6488846","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Myocardial infarction (MI) is the most severe manifestation of coronary artery disease. Guanxinning (GXN), a traditional Chinese medicinal compound, is used to treat stable coronary artery disease. However, the potential benefits of GXN in MI and its precise molecular mechanisms remain unclear. This study aimed to explore the effects and therapeutic mechanisms of GXN in MI by network pharmacology, molecular docking, and experimental validation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using “myocardial infarction” as a search term, we retrieved relevant disease targets from multiple databases, including the Human Mendelian Genetic Disease Database, Drug Database, DisGeNET Database, and GeneCards Human Genetic Synthesis Database. Protein–protein interaction (PPI) networks for the intersecting targets were constructed using the STRING database, and core targets were identified. These were then subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses using the Metascape software. Putative active ingredients and core targets were further analyzed by docking and binding energy calculations using AutoDock Vina (Version 1.2.0), and visualization was performed using PyMOL 2.3.0. Additionally, an acute MI rat model was constructed to verify the results of network pharmacology through in vivo experiments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Network pharmacology analysis predicted 330 potential therapeutic targets of GXN for the treatment of MI, 26 of which were identified as central to its therapeutic effects. GO enrichment analysis identified 1885 relevant biological processes, whereas KEGG enrichment analysis revealed 154 associated signaling pathways. Imaging studies, enzyme-linked immunosorbent assays, Western blot analysis, Masson’s trichrome staining, and TUNEL assays demonstrated that GXN mitigated adverse ventricular remodeling by suppressing oxidative stress through activation of the PI3K/AKT/GSK3β signaling pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GXN effectively suppressed oxidative stress following MI by activating the PI3K/AKT/GSK3β signaling pathway, thereby enhancing cardiac function postinfarction. This study established a theoretical foundation for the potential clinical use of GXN.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6488846","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Point Prevalence of Penicillin Allergy Amongst Inpatients at a UK Tertiary Care Hospital 青霉素过敏在英国三级医院住院患者中的流行程度

IF 2 4区医学

Journal of Clinical Pharmacy and Therapeutics Pub Date : 2026-05-30 DOI: 10.1155/jcpt/1746272

Andre Chan, Cameron Wilson, Huseyin Bilgin, Patryk Majewski, Jonathan Snape, Vikki Connell, Neena Bodasing, Krishna Banavathi, Lavanya Diwakar

{"title":"Point Prevalence of Penicillin Allergy Amongst Inpatients at a UK Tertiary Care Hospital","authors":"Andre Chan, Cameron Wilson, Huseyin Bilgin, Patryk Majewski, Jonathan Snape, Vikki Connell, Neena Bodasing, Krishna Banavathi, Lavanya Diwakar","doi":"10.1155/jcpt/1746272","DOIUrl":"https://doi.org/10.1155/jcpt/1746272","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Penicillin allergy (Pen A) is the most commonly reported drug allergy worldwide, with approximately 10% of the population carrying this label. However, over 90% of these labels are inaccurate. A Pen A label is associated with increased morbidity, mortality, antibiotic resistance and healthcare costs. Pen A delabelling has become a clinical and public health priority, with recent focus on tools like PenFAST for risk stratification in nonspecialist settings. The aim of this work is to determine the prevalence of Pen A among adult inpatients at a large UK teaching hospital and to stratify their risk of allergic reactions using the validated PenFAST tool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>A cross-sectional point prevalence survey was conducted over two days in June 2024 across two hospital sites of the University Hospital of North Midlands. All adult inpatients (excluding maternity wards) were screened for Pen A using demographic data and drug charts. Patients with a Pen A label were assessed using PenFAST. Statistical analysis was performed to determine prevalence and identify risk categories.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1136 inpatients, 16.3% (<i>n</i> = 185, 95% CI: 14.2–18.5) were labelled penicillin allergic. Older patients (> 65 years), women and those admitted to medical wards were more likely to carry the label. Pen A label increased the likelihood of diagnosis with other antibiotic allergies (RR: 3.56, 95% CI: 2.52–5.03). Risk stratification identified 55.6% (<i>n</i> = 85) of patients as low risk (PenFAST ≤ 2), suggesting they could be safely delabelled by nonspecialists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pen A prevalence amongst adult inpatients was higher than expected in this study. A significant proportion of inpatients with Pen A are at low risk of true allergy and can potentially be delabelled by nonspecialists using validated clinical history–based tools.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/1746272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2 4区医学

Journal of Clinical Pharmacy and Therapeutics Pub Date : 2026-05-27